TickerGuard
Buy Day today: Neutral (55) Mixed market breadth · no major macro event
PRTA

Prothena Corporation plc

Healthcare · Biotechnology

8.60$ +1.5% vs. previous close Closing price · As of: Oct 8, 2026

Statements

Income Statement

All figures as a percentage of revenue in the same period.

Tick rows to compare them in a chart (up to 4)

Income Statement PRTA
Line item 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
1,061.9% 5,798.8% 1,640.3% 5,982.7% 111.6% 3,636.5% 11,330.2% 488.9% 10,595.1% 6,245.2% 8,778.9% 41.0% 12.5% 241.4% 2.7% 38.2%
100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% -10,495.1% -6,145.2% 100.0% 100.0% 100.0% 100.0% 100.0% 61.8%
787.4% 4,767.7% 1,284.4% 3,853.8% 75.6% 3,636.5% 11,330.2% 488.9% 10,595.1% 6,245.2% 8,778.9% 41.0% 251.5% 241.4% 164.6% 1,392.5%
291.1% 1,100.4% 373.6% 2,226.5% 37.5% 1,437.8% 3,891.6% 175.2% 4,448.4% 4,390.2% 4,537.3% 23.1% 92.6% 67.7% 49.7% 613.3%
1,078.4% 5,868.0% 1,657.9% 6,080.3% 113.1% 5,074.3% 15,221.8% 664.2% 15,043.5% 4,382.7% 13,316.2% 64.1% 344.1% 309.1% 214.4% 1,967.6%
-978.4% -5,768.0% -1,557.9% -5,980.3% -13.1% -4,974.3% -15,121.8% -564.2% -16,634.0% -10,527.9% -13,216.2% 35.9% -244.1% -209.1% -114.4% -1,905.8%
0.0% 0.0% 0.0% 22.8% 0.0% 0.0% 81.8% 13.4% 387.1% 1,007.7% 971.2% 3.4% 12.4% – – –
-978.4% -5,768.0% -1,557.8% -6,003.1% -12.5% -4,972.7% -15,067.7% -572.7% -16,347.1% -9,496.1% -13,063.0% 35.9% -233.0% -175.6% -95.4% -2,073.8%
25.7% 84.0% 0.2% 61.4% 1.6% 43.6% 108.4% -15.9% -49.2% 46.6% -33.2% 2.5% -16.1% -14.7% -4.9% 446.7%
-1,004.2% -5,852.1% -1,558.0% -6,064.5% -14.1% -5,016.3% -15,176.1% -556.8% -16,297.9% -9,542.6% -13,029.8% 33.4% -217.0% -160.9% -90.5% -2,520.6%
-963.1% -5,690.9% -1,540.3% -5,882.7% -11.6% -4,924.1% -14,891.8% -553.0% -16,010.4% -10,343.2% -12,398.2% 39.3% -242.7% -174.6% -94.7% -2,035.6%

Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?